Aradigm Corp. regained compliance with the Nasdaq listing rule requiring the company to maintain a market value of listed securities of $35 million or greater for 10 consecutive business days.

The specialty pharmaceutical company received a noncompliance notice from Nasdaq on April 4, saying the company did not comply with the minimum requirement of $2.5 million stockholders' equity, or $35 million market value of listed securities, or $500,000 of net income from continuing operations.

Aradigm will continue to be listed on the Nasdaq Capital Market.